Overactive Bladder

Data on SANCTURA for OAB: Patients don't experience daytime sleepiness

Published in Women's Health Weekly, September 23rd, 2004

Indevus Pharmaceuticals, Inc., (IDEV) and Odyssey Pharmaceuticals, PLIVA's specialty-branded subsidiary, announced that new data from a clinical trial with SANCTURA (trospium chloride) presented at the annual meeting of the International Continence Society in Paris, France demonstrated that patients with overactive bladder (OAB) who were treated with the drug did not experience daytime sleepiness.

A total of 658 patients were studied in this 12-week, randomized, double-blind, placebo-controlled trial, which was included in the new drug application for SANCTURA approved by the U.S. Food and Drug Administration on May 28, 2004. In addition to meeting the endpoints of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2004-09-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry